TY - JOUR
T1 - HapMap scanning of novel human minor histocompatibility antigens
AU - Kamei, Michi
AU - Nannya, Yasuhito
AU - Torikai, Hiroki
AU - Kawase, Takakazu
AU - Taura, Kenjiro
AU - Inamoto, Yoshihiro
AU - Takahashi, Taro
AU - Yazaki, Makoto
AU - Morishima, Satoko
AU - Tsujimura, Kunio
AU - Miyamura, Koichi
AU - Ito, Tetsuya
AU - Togari, Hajime
AU - Riddell, Stanley R.
AU - Kodera, Yoshihisa
AU - Morishima, Yasuo
AU - Takahashi, Toshitada
AU - Kuzushima, Kiyotaka
AU - Ogawa, Seishi
AU - Akatsuka, Yoshiki
PY - 2009
Y1 - 2009
N2 - Minor histocompatibility antigens (mHags) are molecular targets of alloimmunity associated with hematopoietic stem cell transplantation (HSCT) and involved in graft-versus-host disease, but they also have beneficial antitumor activity. mHags are typically defined by host SNPs that are not shared by the donor and are immunologically recognized by cytotoxic T cells isolated from post-HSCT patients. However, the number of molecularly identified mHags is still too small to allow prospective studies of their clinical importance in transplantation medicine, mostly due to the lack of an efficient method for isolation. Here we show that when combined with conventional immunologic assays, the large data set from the International HapMap Project can be directly used for genetic mapping of novel mHags. Based on the immunologically determined mHag status in HapMap panels, a target mHag locus can be uniquely mapped through whole genome association scanning taking advantage of the unprecedented resolution and power obtained with more than 3 000 000 markers. The feasibility of our approach could be supported by extensive simulations and further confirmed by actually isolating 2 novel mHags as well as 1 previously identified example. The HapMap data set represents an invaluable resource for investigating human variation, with obvious applications in genetic mapping of clinically relevant human traits.
AB - Minor histocompatibility antigens (mHags) are molecular targets of alloimmunity associated with hematopoietic stem cell transplantation (HSCT) and involved in graft-versus-host disease, but they also have beneficial antitumor activity. mHags are typically defined by host SNPs that are not shared by the donor and are immunologically recognized by cytotoxic T cells isolated from post-HSCT patients. However, the number of molecularly identified mHags is still too small to allow prospective studies of their clinical importance in transplantation medicine, mostly due to the lack of an efficient method for isolation. Here we show that when combined with conventional immunologic assays, the large data set from the International HapMap Project can be directly used for genetic mapping of novel mHags. Based on the immunologically determined mHag status in HapMap panels, a target mHag locus can be uniquely mapped through whole genome association scanning taking advantage of the unprecedented resolution and power obtained with more than 3 000 000 markers. The feasibility of our approach could be supported by extensive simulations and further confirmed by actually isolating 2 novel mHags as well as 1 previously identified example. The HapMap data set represents an invaluable resource for investigating human variation, with obvious applications in genetic mapping of clinically relevant human traits.
UR - http://www.scopus.com/inward/record.url?scp=67149147425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67149147425&partnerID=8YFLogxK
U2 - 10.1182/blood-2008-07-171678
DO - 10.1182/blood-2008-07-171678
M3 - Article
C2 - 18809759
AN - SCOPUS:67149147425
SN - 0006-4971
VL - 113
SP - 5041
EP - 5048
JO - Blood
JF - Blood
IS - 21
ER -